

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6952687

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADIMAB, LLC	01/16/2019
RECEIVING PARTY DATA	
Name:	ICONIC THERAPEUTICS, INC.
Street Address:	701 GATEWAY BLVD, SUITE 100
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17458507
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 570-1000
Email:	ebowen@goodwinlaw.com, us-patentbos@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	ITI-001USC1
NAME OF SUBMITTER:	KUWABO MUBYANA
SIGNATURE:	/Kuwabo Mubyana/
DATE SIGNED:	10/05/2021
Total Attachments: 2	
source=ITI-001WOUS Assignment Adimab to Iconic_Signed#page1.tif	
source=ITI-001WOUS Assignment Adimab to Iconic_Signed#page2.tif	

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **Adimab, LLC**, a Delaware limited liability company, having a place of business at 7 Lucent Drive, Lebanon, New Hampshire 03766 ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to **Iconic Therapeutics, Inc.**, a Delaware corporation, having a place of business at 7000 Shoreline Court, Suite 270, South San Francisco, CA 94080 ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional or non-provisional application filed under 35 U.S.C. § 111, design application filed under 35 U.S.C. § 171, Registered Community Designs, international application filed according to the Patent Cooperation Treaty (PCT), U.S. national phase application filed under 35 U.S.C. § 371, and any patents issuing thereon ("PATENT RIGHTS"):

- International Application No. PCT/US2019/012427, entitled "Anti-Tissue Factor Antibody-Drug Conjugates and Related Methods," filed on January 4, 2019.

2. The entire worldwide right, title, and interest in and to:
(a) the PATENT RIGHTS, including any right of priority; (b) any provisional, divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, transferee, assignee, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


Title:	Anti-Tissue Factor Antibody-Drug Conjugates and Related Methods		
Filed:	January 4, 2019	Attorney Docket #:	34002-41904/WO
Application #:	PCT/US2019/012427		

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNOR

Date of Signature



 [signature]

Jan 16th 2019

ERIC KRAULAND

 Name


CHIEF SCIENTIFIC OFFICER

 Title

Adimab, LLC

Duly Authorized Representative of ASSIGNEE

Date of Signature



 [signature]

Jan 16, 2019

William Greale

 Name

CEO

 Title

Iconic Therapeutics, Inc.
